Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability
Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz
Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz
View: Text | PDF
Research Article Immunology Infectious disease

Heat-killed Mycobacterium tuberculosis prime-boost vaccination induces myeloid-derived suppressor cells with spleen dendritic cell–killing capability

  • Text
  • PDF
Abstract

Tuberculosis patients and mice infected with live Mycobacterium tuberculosis accumulate high numbers of myeloid-derived suppressor cells (MDSCs). Here, we hypothesized that dead M. tuberculosis vaccines also may induce MDSCs that could impair the efficacy of vaccination. We found that repeated injections of M. tuberculosis vaccines (heat-killed M. tuberculosis in incomplete Freund’s adjuvant, such as Montanide) but not single or control vaccines without M. tuberculosis strongly expanded CD11b+ myeloid cells in the spleen, leading to T cell suppression of proliferation and killing ex vivo. Dead M. tuberculosis vaccination induced the generation of CD11b+Ly6ChiCD115+ iNOS/Nos2+ monocytic MDSCs (M-MDSCs) upon application of inflammatory or microbial activation signals. In vivo these M-MDSCs were positioned strategically in the splenic bridging channels and then positioned in the white pulp areas. Notably, within 6–24 hours, in a Nos2-dependent fashion, they produced NO to rapidly kill conventional and plasmacytoid DCs while, surprisingly, sparing T cells in vivo. Thus, we demonstrate that M. tuberculosis vaccine induced M-MDSCs do not directly suppress effector T cells in vivo but, instead, indirectly by killing DCs. Collectively, we demonstrate that M. tuberculosis booster vaccines induce M-MDSCs in the spleen that can be activated to kill DCs. Our data suggest that formation of MDSCs by M. tuberculosis vaccines should be investigated also in clinical trials.

Authors

Eliana Ribechini, Ina Eckert, Andreas Beilhack, Nelita Du Plessis, Gerhard Walzl, Ulrike Schleicher, Uwe Ritter, Manfred B. Lutz

×

Figure 2

Only CD11b+ cells isolated from CFA/CFA mice produce substantial amounts of NO and suppress T cell proliferation.

Options: View larger image (or click on image) Download as PowerPoint
Only CD11b+ cells isolated from CFA/CFA mice produce substantial amounts...
(A) CD11b+ cells from spleen cells of untreated (Ctrl) and CFA-, CFA/IFA-, and CFA/CFA-treated mice were isolated by MACS and compared with in vitro–generated BM-MDSCs for their NO production by Griess assay after overnight stimulation with LPS/IFN-γ. Values correspond to NO production by 2 × 106 cells (3 independent experiments with n = 8 replicates, except BM-MDSCs with n = 6). (B) T cell suppression assays. CFSE-labeled bulk T cells isolated from naive mice were stimulated with CD3/CD28 antibodies and cultured for 4 days with MACS-purified CD11b+ cells from untreated and CFA-, CFA/IFA-, and CFA/CFA-treated mice or in vitro BM-generated MDSCs in the presence or absence of L-NMMA. Example assay showing the gating for proliferated CFSElo cells. (C) Pooled data of individual experiments, as shown in B, are displayed. For T cells only, BM-MDSC, CFA/CFA plus L-NMMA (n = 3). For CTRL, CFA, CFA/IFA, CFA/CFA (n = 4). For BM-MDSC plus L-NMMA (n = 2). (D) Ex vivo bulk T cell proliferation assay. Spleens from untreated (Ctrl, n = 14 mice), CFA- (n = 16), CFA/IFA- (n = 15), and CFA/CFA-treated mice (n = 16) were CFSE labeled and then stimulated with CD3/CD28 antibodies for 4 days. The percentages of proliferated CFSElo cells within the CD4+ and CD8+ T subsets are shown. (E) Ex vivo bulk T cell proliferation assay. CD11b+ cell–depleted spleens from untreated and CFA-, CFA/IFA-, and CFA/CFA-treated mice (n = 3) were CFSE labeled and then stimulated with CD3/CD28 antibodies for 4 days. The percentages of proliferated CFSElo cells within the CD4+ and CD8+ T subsets are shown. Statistical significance was assessed by comparison of sorted cells from control versus treated mice (A) or T cells only versus T cells cocultured with ex vivo–sorted CD11b+ cells from treated mice (C) or bulk splenic T cells from control versus treated mice (D and E). Statistics by 1-way ANOVA with multiple comparisons and Tukey’s post test. **P < 0.01,****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts